Evidence map›Paper›PMID 29270608›Full record

ArticleJAMA oncology2018

Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.

Tsuyoshi Konishi, Yoshifumi Shimada, Meier Hsu, Lauren Tufts, Rosa Jimenez-Rodriguez, Andrea Cercek, Rona Yaeger, Leonard Saltz, J Joshua Smith, Garrett M Nash and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06314958 (Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment), which is not on this map. Cited by 140 papers.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06314958 recruitingnot on this mapstarted 2023, after this paper: background citation

Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment

TypeobservationalSponsorCity of Hope Medical CenterRan2023 to 2028Enrolled400ConditionsColorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage IIIArmsCENSURE
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 257 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Tsuyoshi KonishiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Yoshifumi ShimadaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Meier HsuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Lauren TuftsDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Rosa Jimenez-RodriguezDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrea CercekDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Leonard SaltzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
J Joshua SmithDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Garrett M NashDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
José G GuillemDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip B PatyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Julio Garcia-AguilarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Mithat GonenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Martin R WeiserDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USNiigata University · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

importanceGuidelines recommend measuring preoperative carcinoembryonic antigen (CEA) in patients with colon cancer. Although persistently elevated CEA after surgery has been associated with increased risk for metastatic disease, prognostic significance of elevated preoperative CEA that normalized after resection is unknown.

objectiveTo investigate whether patients with elevated preoperative CEA that normalizes after colon cancer resection have a higher risk of recurrence than patients with normal preoperative CEA. DESIGN, SETTING, AND

participantsThis retrospective cohort analysis was conducted at a comprehensive cancer center. Consecutive patients with colon cancer who underwent curative resection for stage I to III colon adenocarcinoma at the center from January 2007 to December 2014 were identified. EXPOSURES: Patients were grouped into 3 cohorts: normal preoperative CEA, elevated preoperative but normalized postoperative CEA, and elevated preoperative and postoperative CEA. MAIN OUTCOMES AND MEASURES: Three-year recurrence-free survival (RFS) and hazard function curves over time were analyzed.

resultsA total of 1027 patients (461 [50.4%] male; median [IQR] age, 64 [53-75] years) were identified. Patients with normal preoperative CEA had 7.4% higher 3-year RFS (n = 715 [89.7%]) than the combined cohorts with elevated preoperative CEA (n = 312 [82.3%]) (P = .01) but had RFS similar to that of patients with normalized postoperative CEA (n = 142 [87.9%]) (P = .86). Patients with elevated postoperative CEA had 14.9% lower RFS (n = 57 [74.5%]) than the combined cohorts with normal postoperative CEA (n = 857 [89.4%]) (P = .001). The hazard function of recurrence for elevated postoperative CEA peaked earlier than for the other cohorts. Multivariate analyses confirmed that elevated postoperative CEA (hazard ratio [HR], 2.0; 95% CI, 1.1-3.5), but not normalized postoperative CEA (HR, 0.77; 95% CI, 0.45-1.30), was independently associated with shorter RFS. CONCLUSIONS AND RELEVANCE: Elevated preoperative CEA that normalizes after resection is not an indicator of poor prognosis. Routine measurement of postoperative, rather than preoperative, CEA is warranted. Patients with elevated postoperative CEA are at increased risk for recurrence, especially within the first 12 months after surgery.

Indexed as

AdenocarcinomaAgedBiomarkers, TumorCarcinoembryonic AntigenChemotherapy, AdjuvantColonic NeoplasmsDisease-Free SurvivalFemaleHumansMaleMiddle AgedPostoperative PeriodPredictive Value of TestsPreoperative PeriodPrognosisRadiotherapy, AdjuvantBiomarkers, TumorCarcinoembryonic Antigen

Identifiers

PMID29270608
PMCPMC5885834
OpenAlexW2778787212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.